November 20th, 2026Efti Plus Pembrolizumab and RT Yields 81% 12-Month DFS in Soft Tissue SarcomaNeoadjuvant eftilagimod alfa, pembrolizumab, and radiotherapy produced an 81.1% 12-month DFS rate in high-risk, resectable soft tissue sarcoma.Read more
November 21st, 2026Rethinking HCC Surveillance and Treatment Amid a Shifting Risk Landscape“This is the closest we have been to biomarkers replacing ultrasound,” said Amit G. Singal, MD, MS, FAASLD.Read more
November 21st, 2026Sequencing B7-H3 and SEZ6 ADCs With DLL3 Bispecifics in SCLCADCs directed towards B7-H3, SEZ, DLL3, and TROP2 appear to be “super exciting,” according to Anne Chiang, MD, PhD.Read more
November 20th, 2026Rezatapopt Shows Durable Responses in TP53 Y220C-Mutated PROCRezatapopt monotherapy yielded an ORR of 48% in TP53 Y220C-mutated platinum-resistant/refractory ovarian cancer.Read more
November 20th, 2026Tarlatamab Maintenance Leads the Leaps Forward in Small Cell Lung CancerAnne Chiang, MD, PhD, discusses DeLLphi-305 and other leaps forward in small cell lung cancer, along with a setback regarding lurbinectedin.Read more
November 20th, 2026FDA Grants RMAT Designation to iSCIB1+ in Advanced MelanomaThe FDA granted RMAT designation to inzitagene plasmivec for advanced melanoma ahead of a phase 3 trial expected to start in December 2026.Read more
November 20th, 2026Mitochondrial Genetic Variation as a Novel Predictor of Graft-versus-Host Disease After Stem-Cell Transplantation in Myelodysplastic NeoplasmsVariation in the mitochondrial genome carries prognostic information about graft-versus-host disease that current clinical risk scores do not capture. Read more
November 20th, 2026Testosterone Therapy Shows No Added Progression Risk in Active Surveillance PCaTestosterone therapy was not associated with disease progression in a retrospective 3324-patient active surveillance prostate cancer cohort.Read more